Weighing the Risks and Benefits of Coxibs, NSAIDs and Antiplatelet Therapy: Where the Data Lead CME
Program Chairs: Scott D. Solomon, MD; James M. Scheiman, MD; Faculty: Samuel Z. Goldhaber, MD; A. Mark Fendrick, MD
Disclosures

Release Date: February 27, 2006; Valid for credit through February 27, 2007

Contents of This CME Activity

Medscape Editorial Note, February 2, 2006

Emerging information is creating debate about whether the benefits of COX-2 inhibitors ("coxibs") outweigh their cardiovascular risks. In addition, possible adverse effects of standard NSAIDs on the cardiovascular system are under scrutiny. Physicians as well as patients are uncertain about the optimal use of these agents. Medscape's NSAIDs and Cardiovascular Effects Alert Center provides links to articles and/or policy statements that update the evidence in this important therapeutic area. This Center is not intended to be a definitive source on the subject.


  1. Weighing the Risks and Benefits of Coxibs, NSAIDs and Antiplatelet Therapy: Where the Data Lead
    Program Chairs: Scott D. Solomon, MD; James M. Scheiman, MD;
    Faculty: Samuel Z. Goldhaber, MD; A. Mark Fendrick, MD
    Introduction
    Analyzing Cardiovascular Issues Surrounding Traditional NSAIDs and COX-2 Inhibitors
    Bleeding Risks With Combined Anticoagulant/Antiplatelet Therapy
    Minimizing the GI Risks of NSAIDs and Aspirin
    Shifting Patterns in Risk Assessment for Coxib/NSAID Therapy: CV and GI Issues
    References


 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
This CME activity "Weighing the Risks and Benefits of Coxibs, NSAIDs and Antiplatelet Therapy: Where the Data Lead" is based on a CME-accredited satellite symposium held during the annual meeting of the American Heart Association.
Copyright © 2006 SCEPTER.

 
AstraZeneca
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
 
SCEPTER is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

SCEPTER designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.